Zhao Yinyu, Gao Chenxing, Leng Hong
Department of Dermatology, Second Affiliated Hospital of Soochow University, Suzhou, China.
Postepy Dermatol Alergol. 2025 Jun 12;42(3):248-254. doi: 10.5114/ada.2025.152080. eCollection 2025 Jun.
Prurigo nodularis (PN) is a chronic pruritic and inflammatory skin disorder and dupilumab is currently the only biologic agent approved in China for the treatment.
To evaluate the efficacy and safety of dupilumab in managing moderate to severe PN through a retrospective study of 76 patients.
A retrospective analysis was conducted of clinical and laboratory data from PN patients who received regular dupilumab treatment for 52 weeks at the Dermatology Department of the Second Affiliated Hospital of Soochow University between March 2021 and June 2023. Assessments were made at baseline (week 0), and at weeks 4, 8, 16, 26, and 52 using prurigo nodule counts, Investigator's Global Assessment (IGA) scores, Pruritus Numeric Rating Scale (NRS) scores, and Dermatology Life Quality Index (DLQI) scores to evaluate clinical symptoms and pruritus. Adverse events occurring post-treatment were also recorded to assess the drug's safety and efficacy.
A total of 76 patients with moderate to severe PN were included in this study. By week 52, there were significant reductions in prurigo nodule counts, IGA scores, NRS scores, and DLQI scores. Prurigo nodule counts decreased from a baseline of 74.64 ±33.45 to 2.3 ±0.9, IGA scores from 3.53 ±0.54 to 0.54 ±0.33, NRS scores from 7.65 ±2.27 to 1.01 ±0.65, and DLQI scores from 18.46 ±4.53 to 1.55 ±0.68, with all differences being statistically significant ( < 0.05). Seven patients experienced injection site reactions, and 2 patients developed facial erythema, which resolved either spontaneously or with symptomatic treatment. No other adverse events were reported.
Dupilumab effectively reduces the number of PN, improves IGA scores, alleviates pruritus, and enhances quality of life in patients with moderate to severe PN, with a high safety profile.
结节性痒疹（PN）是一种慢性瘙痒性炎症性皮肤病，度普利尤单抗是目前中国唯一获批用于治疗该病的生物制剂。
通过对76例患者的回顾性研究，评估度普利尤单抗治疗中度至重度PN的疗效和安全性。
对2021年3月至2023年6月期间在苏州大学附属第二医院皮肤科接受度普利尤单抗常规治疗52周的PN患者的临床和实验室数据进行回顾性分析。在基线（第0周）以及第4、8、16、26和52周时进行评估，使用结节性痒疹计数、研究者整体评估（IGA）评分、瘙痒数字评定量表（NRS）评分和皮肤病生活质量指数（DLQI）评分来评估临床症状和瘙痒情况。还记录治疗后发生的不良事件，以评估药物的安全性和疗效。
本研究共纳入76例中度至重度PN患者。到第52周时，结节性痒疹计数、IGA评分、NRS评分和DLQI评分均显著降低。结节性痒疹计数从基线时的74.64±33.45降至2.3±0.9，IGA评分从3.53±0.54降至0.54±0.33，NRS评分从7.65±2.27降至1.01±0.65，DLQI评分从18.46±4.53降至1.55±0.68，所有差异均具有统计学意义（<0.05）。7例患者出现注射部位反应，2例患者出现面部红斑，这些反应均自行缓解或经对症治疗后缓解。未报告其他不良事件。
度普利尤单抗可有效减少中度至重度PN患者的结节数量，改善IGA评分，减轻瘙痒，提高生活质量，且安全性高。
